Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | FGFR2 - CCDC6 FGFR2 N549D FGFR2 N549K FGFR2 V564I |
Gene Variant Detail |
FGFR2 - CCDC6 (gain of function) FGFR2 N549D (gain of function - predicted) |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FGFR2 - CCDC6 FGFR2 N549D FGFR2 N549K FGFR2 V564I | cholangiocarcinoma | predicted - resistant | Pemigatinib | Case Reports/Case Series | Actionable | In a Phase I trial (FIGHT-101), a cholangiocarcinoma patient harboring FGFR2-CCDC6 experienced disease progression after initially responding to Pemazyre (pemigatinib), and was found to have acquired FGFR2 N549K, FGFR2 N549D, and FGFR2 V564I (PMID: 35176457; NCT02393248). | 35176457 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|